1. Thomas, J, Jacobson, GA, Narkowicz, CK, Peterson, GM, Burnet, H & Sharpe, C 2010, ‘REVIEW ARTICLE: Toenail onychomycosis: an important global disease burden’, Journal of Clinical Pharmacy and Therapeutics, vol. 35, no. 5, pp. 497–519.
2. Eertmans, F, Doss, N, Rossel, B & Regidor, P-A 2017, ‘Nail Acidification versus Amorolfine in the local management of Onychomycosis. A Comparative, Prospective, Randomized, Blinded Trial.’, International Educational Applied Scientific Research Journal, vol. 2, no. 5.
3. Eertmans, F, Doss, N, Rossel, B & Adriaens, E 2018, ‘Daily Application of an Aqueous, Acidifying, Peelable Nail Polish versus Weekly Amorolfine for Topical Onychomycosis Treatment: A Prospective, Randomized, Blinded Trial’, Dermatology and Therapy, vol. 8, no. 3, pp. 463–473.
4. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236: 1-26.
5. Piérard GE., Piérard-Franchimont C. & Quatresooz P. Fungal thigmotropism in onychomycosis and in a clear hydrogel pad model. Dermatology 2007; 215: 107–113.
6. Brown MB et al. Overcoming the nail barrier: a systematic investigation of ungula chemical penetration enhancement. Int J Pharm. 2009; 370(1-2): 61-67.
7. Chouhan P., Saini TR Hydration of nail plate: a novel screening model for transungual drug permeation enhancers. Int J Pharm. 2012; 436(1-2): 179-182.
8. Büsing K. et al. Antifungal effects of ethyl pyruvate, ethyl lactate and butyl lactate on selected dermatophytes. Mycoses 2008; 51: 365–436.
9. Göbel A. et al. 1,2-pentanediol enhances cutaneous penetration and bioavailability of active ingredients. 2009. J. Am. Acad Dermatol AB82.